)
CorMedix (CRMD) investor relations material
CorMedix Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Definitive agreement to acquire substantially all of Heron’s commercial and pipeline assets; closing targeted for Q1 2027, subject to Heron stockholder approval, regulatory clearance and customary conditions.
Deal rationale includes broader revenue diversification and commercial leverage; Heron’s portfolio generated ~$150 million in trailing-12-month net product revenue, with $125 million to $150 million of acquired-product revenue forecast for pro forma 2027.
Expected annualized operating cost synergies of $45 million to $60 million by end-2027; transaction expected to be immediately accretive to earnings and free cash flow after closing.
Voting matters and shareholder proposals
Heron stockholder approval is a closing condition; Heron intends to file a Schedule 14A proxy statement and mail the definitive proxy to stockholders.
Heron and the acquirer, along with their respective directors and executive officers, may be deemed participants in the proxy solicitation; additional participant-interest disclosures are to be included in transaction materials.
Risk oversight and compliance
Closing and expected transaction benefits face risks including failure to obtain approval or regulatory clearance, failure to satisfy closing conditions, integration challenges, and inability to realize anticipated synergies or accretion.
Other identified risks include potential transaction termination, litigation, unexpected costs or delays, business disruption, management distraction and uncertainty about post-close operations and strategy.
- Post-TDAPA pricing weighed on Q3 as Heron and REZZAYO offer 2027 growth potential.CRMD
Q3 2026 - Heron deal adds four products, with closing targeted for Q1 2027 and $45M–$60M in synergies.CRMD
Proxy filing - Heron deal adds four marketed products, with up to $55M in earn-outs and $45M–$60M synergies projected.CRMD
Proxy filing - Four marketed products expand institutional-care reach, with $45–$60 million in annual synergies targeted by 2027.CRMD
M&A announcement - Diversified portfolio, strong cash flow, and new market opportunities drive growth and expansion.CRMD
Wells Fargo 21st Annual Healthcare Conference - Strong revenue growth, pipeline expansion, and financial flexibility drive continued value creation.CRMD
Corporate presentation - Q2 2026 revenue hit $101.9M, up 157%, with strong DefenCath and Melinta sales and raised guidance.CRMD
Q2 2026 - Diversified portfolio and robust pipeline drive growth, targeting major unmet needs in anti-infectives.CRMD
Investor Day 2026 - First profitable quarter: $39.1M revenue, $20.6M net income, H1 guidance at $70M.CRMD
Q1 2025
)
)
)
)
)
)
)
)